Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Blood cancer journal·2026
Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Blood cancer discovery·2026
Same author

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Blood advances·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Assessing patient perspectives on enrollment in lymphoma clinical trials.

Cancer·2026

Related Experiment Video

Updated: May 20, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Examining racial differences in diffuse large B-cell lymphoma presentation and survival.

Christopher R Flowers1, Pareen J Shenoy, Uma Borate

  • 1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

Leukemia & Lymphoma
|July 18, 2012
PubMed
Summary

Black patients with diffuse large B-cell lymphoma (DLBCL) often present with more severe symptoms. However, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) improved survival for all races.

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Related Experiment Videos

Last Updated: May 20, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma.
  • Racial disparities in cancer presentation and outcomes are well-documented.
  • Understanding these disparities in DLBCL is crucial for equitable treatment.

Purpose of the Study:

  • To investigate racial differences in the clinical presentation and outcomes of diffuse large B-cell lymphoma (DLBCL).
  • To evaluate the impact of R-CHOP therapy on survival across different racial groups with DLBCL.

Main Methods:

  • Retrospective cohort analysis of 701 DLBCL patients (1981-2010).
  • Comparison of demographic, clinical presentation, and treatment data between white and black patients.
  • Survival analysis stratified by race and treatment regimen (CHOP vs. R-CHOP).

Main Results:

  • Black patients were diagnosed at a younger median age (50 vs. 57 years) and presented with more severe disease indicators (elevated LDH, B-symptoms, poor performance status).
  • No racial differences were observed in the utilization of R-CHOP chemotherapy.
  • While black race predicted worse survival with CHOP alone, R-CHOP treatment significantly improved survival outcomes irrespective of race.

Conclusions:

  • Racial disparities exist in DLBCL presentation, with black patients exhibiting more advanced disease at diagnosis.
  • R-CHOP therapy demonstrates a survival benefit for DLBCL patients, effectively mitigating the negative prognostic impact of race observed with older chemotherapy regimens.
  • Further research into biological factors underlying these racial differences is warranted to optimize DLBCL treatment strategies.